Phase 3 data indicates that once-daily Zasocitinib may be as effective as injectable biologics in achieving skin clearance. The data suggests a potential rival to injectable biologics for this purpose. Zasocitinib's efficacy in this area has been demonstrated in a phase 3 setting.